Deferiprone modulates osteoclast‐mediated bone resorption while preserving axial bone microstructure in β‐thalassemic mice with iron overload
Deferiprone (DFP), an iron chelator, is widely used to alleviate iron overload. However, its effects on bone metabolism remain incompletely understood. Herein, we demonstrated that DFP reduced osteoblast viability and in vitro mineralization. Interestingly, DFP delayed osteoclastogenesis, suppressed osteoclast marker expression, and appeared to influence iron efflux by upregulating Nrf2 and ferroportin-1. Although DFP effectively reduced iron accumulation in bone, it did not reverse persistent microstructural defects in the axial skeleton of β-thalassemic mice. Under high-iron conditions, DFP appeared to increase osteoclast turnover, leading to a transient accumulation of multinucleated osteoclasts followed by enhanced apoptosis. Collectively, our findings suggest a trade-off whereby reduced iron toxicity is accompanied by attenuated bone formation and resorption in β-thalassemic mice.
Authors
- Jirawan Thongbunchoo
- Jarinthorn Teerapornpuntakit (ORCID: https://orcid.org/0000-0001-5012-0842)
- Jiraporn Panmanee (ORCID: https://orcid.org/0000-0003-1541-7995)
- Parinda Jamrus
- Ratchaneevan Aeimlapa (ORCID: https://orcid.org/0000-0001-8669-2818)
- Nuttanan Pholngam
- Narattaphol Charoenphandhu (ORCID: https://orcid.org/0000-0002-2189-6542)
- Saovaros Svasti (ORCID: https://orcid.org/0000-0001-8334-9838)
- Pathnaree Wattano
- Benjaporn Kiatpakdee
Institutions
- Thammasat University (TH)
- Mahidol University (TH)
- Office of the Royal Society (TH)
Publication Details
- Journal
- FEBS Letters
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1002/1873-3468.70504
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00